Moderna (NASDAQ:MRNA) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Moderna (NASDAQ:MRNA) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Moderna (NASDAQ:MRNA) was given a new $18.00 price target on by analysts at UBS Group AG.
Moderna (NASDAQ:MRNA) had its price target raised by analysts at Leerink Partners from $15.00 to $18.00. They now have an "underperform" rating on the stock.
Moderna (NASDAQ:MRNA) had its price target lowered by analysts at Royal Bank Of Canada from $28.00 to $25.00. They now have a "sector perform" rating on the stock.